Hui Feng

Shanghai Junshi Biosciences Co., LTD

Shanghai

China

SCHOLARLY PAPERS

3

DOWNLOADS

218

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Number of pages: 35 Posted: 16 Apr 2021
Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Guangzhou Medical University - Affiliated Cancer Hospital & Institute, Fudan University - Department of Radiation Oncology, Huazhong University of Science and Technology - Cancer Center, Guangdong Medical University - Affiliated Hospital, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Central South University - Hunan Cancer Hospital, Fujian Provincial Cancer Hospital, Fujian Medical University - Fujian Provincial Hospital, People’s Hospital of Guangxi Zhuang Autonomous Region, Sichuan University - West China Hospital, Central South University - Second Xiangya Hospital, Taichung Veterans General Hospital, Shantou University Medical College - Cancer Hospital, Jiangsu Cancer Hospital, Chang Gung University - Chang Gung Memorial Hospital, National Cancer Centre Singapore, Southern Medical University - Department of Oncology, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Sun Yat-sen University (SYSU) - Fifth Affiliated Hospital, Huazhong University of Science and Technology - Tongji Hospital, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Union Hospital, Hebei Medical University - Fourth Hospital, Hainan Medical University - Hainan General Hospital, Liuzhou Worker’s Hospital, China Medical University - College of Medicine, National Yang-Ming Chiao Tung University - Institute of Clinical Medicine, National Cheng Kung University - National Cheng Kung University Hospital, Tan Tock Seng Hospital, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, TopAlliance Biosciences and Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Downloads 106 (345,764)

Abstract:

Loading...

Nasopharyngeal Carcinoma, anti-PD-1 antibody, Toripalimab

2.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 80 (411,793)

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib

3.

Safety, Efficacy and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Number of pages: 139 Posted: 26 Nov 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Harbin Medical University - Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD and Peking University - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
Downloads 32 (611,728)

Abstract:

Loading...

Neuroendocrine neoplasm, NET, NEC, PD-1,toripalimab